Solizmestrocel for respiratory distress syndrome

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 25 Dec 2023: Trial started, NCT07439848
  2. 27 Feb 2026: Trial registered, NCT07439848

The trials

NCT07439848: Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis

State
Under way
Phase
Phase 1 and Phase 2
People
15 planned
Started
25 Dec 2023
Primary completion
Dec 2026
Arms
Umbilical Cord Mesenchymal Stem Cell (UC-MSC)
Results
None posted
  1. 25 Dec 2023: Trial started
  2. 27 Feb 2026: Trial registered

NCT07479043: To Evaluate the Safety and Potential Therapeutic Activity of JadiCell™, an Investigational Umbilical Cord-Derived Mesenchymal Stem Cell Therapy, in Patients Diagnosed With Acute Respiratory Distress Syndrome (ARDS).

State
Not started
Phase
Phase 3
People
128 planned
Started
1 Mar 2027
Primary completion
31 Oct 2027
Arms
Treatment
Results
None posted
  1. 18 Mar 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Also known as Human Allogenic Umbilical Cord Mesenchymal Stromal Cells, Subjects in the UC-MSC treatment group will receive two intravenous infusions (at day 0 and 3) of 100 million UC-MSC., Uc-msc, Umbilical Cord-Derived Mesenchymal Stem Cells, XytriX.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.